腎臟移植提高了在患有勃起功能障礙的患者中西爾地那菲爾酸的有效性. 一个单一中心的视角
Hany M El Hennawy1, Omar Safar2, Abdullah S Al Faifi1
1Surgery Department, Section of Transplantation, Armed Forces Hospitals Southern Region, Khamis Mushayte, Kingdom of Saudi Arabia.
Transplantation proceedings
|July 6, 2024
概括
西尔德纳菲尔在血液透析患者和放射治疗 (RT) 后持续性勃起功能障碍患者中有效治疗勃起功能障碍 (ED). 治疗后的RT患者对西尔德纳菲尔治疗的反应率显著提高.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 腎臟病學 (nephrology) 是一種醫學專業.
- 在瘤学瘤学.
背景情况:
- 勃起功能障碍 (ED) 是接受血液透析 (HD) 和接受放射治疗 (RT) 的患者的常见并发症.
- 西尔德纳菲尔酸盐是一种固酶5型抑制剂,用于治疗ED.
- 有限的数据存在于这些特定患者群体中西尔德纳菲尔的疗效.
研究的目的:
- 为了比较西尔德纳菲尔酸盐在治疗HD患者的ED治疗中的疗效和安全性,与在RT后一年持久性ED患者相比.
- 确定影响这些群体治疗反应的因素.
主要方法:
- 一项前性队列研究,涉及24名患有HD的患者 (A组) 和13名患有ED的后RT患者 (B组).
- 开始时,西尔德纳菲尔的剂量为25毫克,可能会增加到50毫克.
- 治疗前后使用阿拉伯语翻译的国际勃起功能指数 (IIEF) 调查问卷评估疗效.
主要成果:
- 总体上,西尔德纳菲尔的疗效在A组为40.9%,在B组为76.9%.
- 在B组 (p = .002) 观察到IIEF得分的显著改善,但A组 (p = .458) 没有.
- 在这两组中,常见的副作用包括高血压,胃肠道症状和脸红.
结论:
- 放射治疗可能会增强西尔德纳菲尔在治疗勃起障碍时的有效性.
- 年轻的RT后患者中度至重度ED和更短的透析持续时间显示出更好的结果.
- 席尔德纳菲尔似乎是一个可行的治疗选择在选择后RT患者ED.
相关概念视频
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
144
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
144
01:11Renal Failure: Dose Adjustments
79
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
79
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
152
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
152
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
419
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
419
01:23Antihypertensive Drugs: Vasodilators
502
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
502
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
166
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
166